North Carolina pharmaceutical company Pozen (NASDAQ:POZN) has named an AstraZeneca (NYSE:AZN) veteran to its board of directors, a key move as the company prepares to take a product to market on its own for the first time.
Martin Nicklasson‘s experience spans both large and small pharmaceutical companies. At AstraZeneca, Nicklasson held various executive positions from 1999 through 2007 that include executive vice president of global marketing and business development, and executive vice president of the company’s gastrointestinal franchise. Nicklasson is currently a senior partner at Nicklasson Life Science, an independent consultancy and advisory company to the pharmaceutical and biotechnology sector.
Behavioral Health, Interoperability and eConsent: Meeting the Demands of CMS Final Rule Compliance
In a webinar on April 16 at 1pm ET, Aneesh Chopra will moderate a discussion with executives from DocuSign, Velatura, and behavioral health providers on eConsent, health information exchange and compliance with the CMS Final Rule on interoperability.
“(Nicklasson’s) years of pharmaceutical and life science experience will serve us well as we embark upon our new strategy,” CEO John Plachetka said in a statement.
Chapel Hill, North Carolina-based Pozen has two U.S. Food and Drug Administration-approved products; each of them commercialized with a pharmaceutical partner. Arthritis drug Vimovo was commercialized with AstraZeneca. Migraine treatment Treximet was commercialized with GlaxoSmithKline (NYSE:GSK). The “new strategy” Plachetka refers to is Pozen’s “PA” program, which will offer patients the benefits of aspirin in a safer form. The program’s lead drug candidate, PA 32450, is indicated for use in cardiovascular disease prevention. The drug candidate is currently in phase 3 clinical trials. Pozen expects to file a new drug application with the FDA in 2012.
